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J Clin Psychiatry . Author manuscript Page / 2 10 worldwide decrease in HT prescription. While differences in vulnerability to psychiatric disorders and the role played by HT remains an important question to be addressed, it is however, unlikely to be answered in the near future by large-scale randomized-controlled trials (RCTs) with long-term HT users. On the other hand, it is currently feasible to use existing data from large-scale longitudinal population-based studies with adequate information on hormone exposure and psychiatric evaluation. The present study aimed to determine whether HT could be associated with a lower incidence of depressive symptomatology in a large population-based cohort of postmenopausal women. The impact of HT discontinuation on depressive symptoms was also evaluated. In this study we controlled for socio-demographic variables, measures of physical health including insomnia, as well as cognitive impairment, which may independently contribute to both depression and HT prescription. We also took into account the history of depression as well as the type of HT used.
Method

Study population
The data used for this analysis were derived from a general population study of neuropsychiatric disorders in community-dwelling French elderly (3C Study). Eligible participants, who were at least 65 years of age and non-institutionalized, were recruited from the electoral rolls of three French cities (Bordeaux, Dijon, Montpellier) between 1999 and 2001. The study protocol was approved by the Ethical Committee of the University Hospital of Kremlin-Bic tre. After obtaining written informed consent from all participants, ê interviews were administered by trained staff at baseline and every two years thereafter. The 3C study has been described in further detail elsewhere.10
Outcome measures
The Centre for Epidemiologic Studies Depression Scale (CESD) is a 20-point questionnaire designed to measure current depressive symptoms in the general population which has been validated in the elderly. It has been suggested that a cutoff point of 23 or more can 11 be used to identify major depressive disorder (MDD).
The diagnosis of lifetime psychiatric disorders was made using the 12
Mini-International Neuropsychiatry Interview (MINI), a standardized psychiatric examination which has been validated in the general population according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria. 13 14 Women scoring 23 or over or those taking antidepressants were considered as having current depressive symptomatology in this analysis. Incident cases of depressive symptoms were identified from subjects who had neither depressive symptoms (CESD<23), nor were using antidepressants at baseline, but who subsequently presented with high depressive symptomatology or reported antidepressant treatment during at least one of the two follow-up examinations.
Hormone therapy and menopausal characteristics
All types of medication used during the preceding month (including HT and antidepressants) were validated by presentation of the prescription or the medication itself. Information was also recorded on past HT type, time of initiation, and duration of use, as well as age at menopause (defined as one year without menses) and type of menopause ( natural surgical or following a treatment such as i.e. vs. chemotherapy or radiotherapy).
Socio-demographic and clinical variables
The standardized interview included questions on demographic characteristics, education level, height and weight. Information was obtained on type and quantity of alcohol consumption (number of g of alcohol per day) and tobacco use. Participants were classified as disabled if they were unable to complete at least one task from either the Instrumental Activities of Daily Living (IADL) or the 15 schooling), widowhood, cognitive impairment, insomnia, history of chronic disorders, disability, age at menopause (continuous), and past depression. For the variables which were treated as continuous the linearity assumption was checked. In longitudinal analysis we used multi-adjusted logistic regression models to evaluate the predictive value of HT taken at baseline on new-onset depressive symptoms over 4-year follow-up. We also evaluated these risks for women who have taken HT continuously, or those who have stopped during the 4-year follow-up compared to never users, using the multi-adjusted models (see above). SAS version 9.1 (SAS Institute, Inc., North Carolina) was used for the statistical analysis with a significance level of p<0.05.
Results
Population characteristics as a function of HT use
Of the women recruited as part of the 3C Study (n 5644), only non-demented women (diagnosed using DSM-IV revised criteria ),
with complete follow-up data, who were assessed for depressive symptomatology, who had information relating to the use of HT and had no missing data for the main covariates considered in the multivariate logistic models (n 4069), were included in this analysis. Women not = included in this analysis had a lower educational level, were older, more likely to have disabilities and cognitive dysfunction (p<0.001) and
were more frequently widowed (p 0.002). They were also more likely to have lifetime depression and use antidepressants (p<0.01) and = less likely to use or have used HT (p<0.0001). There were no significant differences regarding the other variables between the excluded subjects and those included in this analysis.
The 4069 women included in the present analysis had a mean (SD) age of 73.6 (5.0), ranging from 65 to 93 years. In our sample, 14.7 currently used HT and 19.9 reported past use. The median (min, max) duration of past HT use was 5 years (1 39) and 12 (1 43) for Current, past and never HT users differed significantly on most socio-demographic and clinical characteristics except tobacco consumption, current antidepressant use, hypercholesterolemia, and asthma ( ). Never users were significantly older, more Table 1 frequently widowed, and more frequently reported natural menopause than ever (current or past) users. Never and past users did not differ significantly regarding the other health variables (including the vascular ones). On the other hand, current users of HT appeared different to both past and never users. They were younger, less frequently widowed, had significantly higher education levels, a higher age at menopause and lower BMI. They were also less likely to have physical disabilities, cognitive impairment, insomnia, chronic disorders ( ischemic or non-ischemic pathologies, diabetes, high blood pressure) and breast cancer. Current users were more frequently alcohol e.g. consumers, had used HT later and for a longer period than past users, and were more likely to have thyroid dysfunction.
Population characteristics as a function of depressive symptoms
At baseline, 21.9 of women were identified as having depressive symptoms (CESD 23) or were currently using antidepressant.
% ≥
Depressed women were older, more frequently widowed, and with a higher percentage of physical or cognitive impairments, insomnia and past major depression ( ). They also reported a lower age at menopause. Among the women who were not depressed at baseline Table 2 (CES-D<23 and not using antidepressants), 17.4 were identified as having depressive symptoms over the 4-year follow-up period. % Women who developed new onset of depressive symptoms were older and with a higher percentage of disability, insomnia, and past major depression than women without depressive symptoms. Compared to women having baseline depressive symptoms they were however less frequently widowed and with a lower percentage of physical or cognitive impairment, insomnia, or past depression and reported a higher age at menopause.
Associations between current HT and incident depressive symptoms
The effect of current HT on incident depressive symptoms was evaluated longitudinally during follow-up after controlling for a large number of covariates, age, education level, center, widowhood, age of menopause, insomnia, physical disabilities, cognitive e.g.
impairment, chronic disorders and past depression (
). Overall, there was no significant adjusted association between baseline HT Table 3 use and new-onset depressive symptoms (p 0.06). HT duration was not significantly associated with depressive symptoms (p 0.78, data In fully adjusted models, we found no significant association between the continuous use of HT and new-onset depressive symptoms (
). The results were the same regardless of the type of HT used (data not shown), however with such small numbers in each of the Table 4 sub-groups, this could likely result from a lack of statistical power. On the other hand, women having stopped their treatment early after inclusion, were at significantly increased risk of new-onset depressive symptomatology (OR 2.63, 95 CI 1.52 4.55). criterion validity in the identification of MDD. , 13 23 Interestingly, the results of our work do suggest that the effects of HT on depression in postmenopausal women may vary depending on the type of treatment used. CEE for example, is most commonly used in the United States but not necessarily elsewhere around the world, which may help explain some inconsistencies in findings across studies. We also found that women who used transdermal 24 estradiol associated with a synthetic progestin had an increased risk of depressive symptoms, while transdermal estradiol alone or in combination with natural progesterone was not significantly associated with the incidence of depressive symptoms. Although we could not definitively conclude to a specific deleterious effect of associated progestin compared to progesterone, our data are supported by previous studies which have shown that the effects of HT on mood can be modified by changing the progestogens compound that is used. Synthetic progestin has been suggested to be an antagonist to estrogen and mitigate its mood-enhancing effect in postmenopausal women. , , A 7 8 25 negative effect on mood pattern was also reported in non-depressed postmenopausal women treated with progestogen in combination with estrogen, whereas no significant change or an improvement in mood was observed with estrogen alone.
Other studies however, 26 -29 reported no negative effect or even mood improvement. ,
Although the results of our study do not suggest that the use of transdermal 30 31 estradiol with synthetic progestin actually causes depressive symptoms, the presence of a significant associations warrants further investigation to help clarify the long-term effects of specific subtypes of progestins on depression.
Discontinuing HT and new-onset depressive symptoms in postmenopausal women
An intriguing finding from this study was the observed increased risk of new-onset depressive symptoms (OR 2.63 95 CI 1.52 4.55, = % p 0.0005) among women who stopped HT early on during the follow-up period, however there was no significant difference between = continuous HT users and never users. This raises the question of why women stopped using HT. Examining group differences, past HT users at baseline differed from never users by being younger and less frequently widowed. Compared to current users, past users were older, less educated, more likely to be widowed and reported more frequently insomnia and a higher level of chronic disorders and disability, at higher risk of depression. However, among current users at baseline, women who discontinued HT early after i.e. a priori inclusion did not differ significantly from those having continuously used HT during the 4-year follow-up period, except for a higher BMI in the early discontinuing group. In addition, this association between discontinuing HT and the incidence of depressive symptoms Hormone therapy and late-life depression J Clin Psychiatry . Author manuscript Page / 5 10 persisted after adjustment for all potential confounders. In our multiadjusted model, BMI was not considered as an adjustment variable since it was not significantly associated with depressive symptoms in univariate analysis (p 0.32). However, since continuing and early = discontinuing women only differed by BMI among all the variables examined, we performed an additional multivariate model further adjusting for BMI; this did not modify the strength of the association and the same OR was observed (OR 2.66 95 CI 1.54 4.60, p = % -= 0.0005). Another possibility could be that discontinuation of HT increases the risk of depressive symptoms due to the (re)emergence of menopause-associated symptoms, particularly in those women who first initiated treatment for the control of menopause-associated depression. Vasomotor symptoms for example, have been independently associated with an increased risk of depression in peri-menopausal women although this appears more unlikely in our older postmenopausal women who are on average 20 years 32 post-menopause. We also observed no difference regarding the frequency of insomnia between continuing and discontinuing women. 33
Women with depressive symptoms may also be more likely to complain of menopausal symptoms and thus to be prescribed HT in the first place. We effectively observed that ever users of HT tended to have a more frequent history of past MDD, although controlling for a past history of depression did not modify the significance of the association. On the other hand, the risk was not significant for those having continued HT. Early or current stressful events have been reported to be associated with depression notably during the menopausal transition. We have no information concerning specific stressful life events during the follow-up except bereavement; where there was 34 no difference in the frequency of widows, between women who developed depressive symptoms during the follow-up period and those with no depressive symptoms. Hence, the underlying biological, neurochemical, or psychological mechanisms associated with re-emergence of depressive symptoms remains to be determined, but could include other processes altering the quality of life and overall functioning, increased proinflammatory activity or sexual dysfunction. e.g. 35
An increase in mood disturbance among postmenopausal women due to declining prescriptions of HT may thus be anticipated.
Interestingly, Mc Intyre et al. reported that the decrease in the number of HT prescriptions following the WHI results in 2002, was associated with a statistically significant concomitant increase in prescriptions of serotonergic antidepressants, suggesting that antidepressants were being prescribed for symptoms (psychological, physical) previously controlled with the use of HT. Data on the 36 appropriate management of depression in the context of HT discontinuation are, however, lacking and require further investigation. , 37 38
Limitations
This study has several limitations. Women taking antidepressants were classified as depressed, although it is possible that the treatment was prescribed for another psychiatric condition. This could have resulted in misclassification bias, however we have ensured that the findings were comparable if we considered only CESD scores and adjusted for antidepressant use in the analysis (data not shown).
The data concerning some of the covariates were self-reported and may thus be subject to recall bias with depressed participants responding more negatively about their health. However, similar associations were seen in the unadjusted and adjusted analysis, thus suggesting that any bias did not have a substantial influence on the results. There is also the potential for bias in this analysis due to the exclusion of women with missing data. These women were older, with lower education level, more frequently widowed and with overall poorer health. In addition, there is prescription bias in regard to women who are given HT and we have shown that current users were significantly healthier than both past and never users. Therefore, despite controlling for a number of variables related to this, other factors which were not recorded, may have influenced the results.
Strengths
Despite these limitations, this study has a number of strengths. The data used in this analysis came from a large multicentre population-based prospective study of women aged 65 years and over and therefore the results are relevant to elderly women living in the community. Psychiatric evaluation was assessed by trained staff using a measure of depressive symptoms which has been validated in the elderly and appears to be a good indicator of MDD. The cohort design of this study allowed evaluation of long-term HT use and 11 12 current HT use was verified at inclusion and at each follow-up by examining the prescriptions and medications themselves, thus minimizing exposure misclassification. We controlled for a large number of covariates linked to depression, thus minimizing any confounding, particularly measures of physical health (physical incapacities, chronic health conditions), insomnia and cognitive impairment. Finally, in contrast to the majority of community-based studies, we controlled for a history of past depression, which may confound the association between depressive symptoms and HT.
Conclusion
HT is still the first-line of treatment for the approximate 75 of women who experience menopausal symptoms and it remains an women should or should not use HT, our study suggests that practitioners may need to monitor more closely women who decide to Hormone therapy and late-life depression J Clin Psychiatry . Author manuscript Page / 6 10 discontinue HT treatment, in particular with regard to breakthrough psychiatric symptoms and offer possible alternative treatments in the case of (re)emergence of depressive symptoms. , 38 41 J Clin Psychiatry . Author manuscript Page / Table 1   Table 3 Adjusted models for the association between HT use and new-onset depressive symptoms after 4-year follow-up, among women without depression at baseline. 0.37 (n 10) Other unrelated HT types = nd nd nd a Corresponds to opposed and unopposed estradiol-based HT.
HT use at baseline (n) a
b Adjusted for age, educational level, centre, widowhood, age at menopause, insomnia, disability, cognitive impairment, chronic health disorders and history of depression.
Hormone therapy and late-life depression J Clin Psychiatry . Author manuscript Page / 10 10 b Adjusted for age, educational level, centre, widowhood, age at menopause, insomnia, disability, cognitive impairment, chronic health disorders and history of depression. Abbreviation: HT: Hormonal Therapy; nd: not determined.
Table 4
Adjusted models for the association between HT use after the inclusion and new-onset depressive symptoms after 4-year follow-up, among women without depression at baseline.
(n HT use )
Depressive symptoms ( ) % OR a 95 CI [ % ] 0.0005 a Adjusted for age, educational level, centre, widowhood, age at menopause, insomnia, disability, cognitive impairment, chronic health disorders and history of depression. b discontinuing between the inclusion and the first 2-year follow-up.
Abbreviation: HT Hormonal Therapy. 
